Connect Biopharma Holdings Limited (CNTB)
| Market Cap | 132.83M |
| Revenue (ttm) | 233,000 -99.1% |
| Net Income | -64.61M |
| EPS | -1.15 |
| Shares Out | 56.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,536 |
| Open | 2.380 |
| Previous Close | 2.360 |
| Day's Range | 2.320 - 2.450 |
| 52-Week Range | 1.230 - 3.820 |
| Beta | -0.18 |
| Analysts | Strong Buy |
| Price Target | 7.25 (+208.51%) |
| Earnings Date | May 12, 2026 |
About CNTB
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Financial Performance
In 2025, CNTB's revenue was $64,000, a decrease of -99.75% compared to the previous year's $26.03 million. Losses were -$55.48 million, 255.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CNTB stock is "Strong Buy." The 12-month stock price target is $7.25, which is an increase of 208.51% from the latest price.
News
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid...
Connect Biopharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Connect Biopharma (CNTB) with an Overweight rating and $4 price target The company’s Phase 2 SEABREEZE STAT readouts in acute asthma and acute COPD are…
Connect Biopharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Connect Biopharma (CNTB) with an Overweight rating and $4 price target
Connect Biopharma Holdings Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Rademikibart shows rapid, durable improvements in asthma and COPD, with unique bronchodilation and eosinophil-lowering effects. SEABREEZE’s mid-2026 readout will guide phase III plans, and commercialization will focus on seamless acute-to-chronic care transitions.
Connect Biopharma files to sell 6.13M ordinary shares for holders
08:33 EDT Connect Biopharma (CNTB) files to sell 6.13M ordinary shares for holders
Connect Biopharma Holdings Registration statement: Registration filing
Connect Biopharma Holdings filed a registration statement on May 15, 2026, providing details about a securities offering with the SEC.
Connect Biopharma Holdings Slides: Corporate presentation
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transfo...
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
Connect Biopharma Holdings Earnings release: Q1 2026
Connect Biopharma Holdings released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Connect Biopharma Holdings Quarterly report: Q1 2026
Connect Biopharma Holdings has published its Q1 2026 quarterly earnings report on May 12, 2026.
Connect Biopharma announces enrollment in Seabreeze STAT study
Connect Biopharma (CNTB) announced that the independent Data Monitoring Committee overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the company’s next-generation an...
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans...
Connect Biopharma director buys $4.0M in common stock
In a regulatory filing, Connect Biopharma (CNTB) disclosed that its director James Huang bought 1.16M shares of common stock on March 31 in a total transaction size of $4.0M. Shares…
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breakin...
Connect Biopharma Holdings Annual report: Q4 2025
Connect Biopharma Holdings has published its Q4 2025 annual report on March 31, 2026.
Connect Biopharma Holdings Earnings release: Q4 2025
Connect Biopharma Holdings released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Connect Biopharma Holdings Transcript: Study result
Rademikibart IV showed rapid, robust FEV1 improvements in asthma and COPD, with effects seen within 15 minutes and sustained for 29 days, outperforming existing therapies. Atopic dermatitis results demonstrated high long-term efficacy and low conjunctivitis rates. Top-line results from ongoing acute exacerbation studies are expected mid-year.
Connect Biopharma Holdings Press release: Study result
Connect Biopharma Holdings issued a press release on March 30, 2026, disclosing material business information to investors.
Connect Biopharma Holdings Slides: Study result
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on March 30, 2026.
Connect Biopharma announces results from rademikibart study
Connect Biopharma (CNTB) announced results from a Phase 3 52-week study in patients with moderate-to-severe atopic dermatitis conducted by the company’s partner in China, Simcere Pharmaceutical, which...
Connect Biopharma Announces $20.2 Million Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“C...
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients –
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many patients experiencing ...
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on tran...